Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 7885 to 7888 of 7888 entries
Sorted by: Best Match Show Resources per page
The Synergistic Effect of .

Drug design, development and therapy

Ke J, Li MT, Huo YJ, Cheng YQ, Guo SF, Wu Y, Zhang L, Ma J, Liu AJ, Han Y.
PMID: 34429584
Drug Des Devel Ther. 2021 Aug 14;15:3543-3560. doi: 10.2147/DDDT.S318515. eCollection 2021.

PURPOSE: We aimed to investigate potential synergistic antiplatelet effects of METHODS: Arachidonic acid (AA), platelet activating factor (PAF), adenosine 5'-diphosphate (ADP) and collagen were used as inducers. The antiplatelet effects of GBE50, aspirin and 1:1 combination of GBE50 and...

Cite
Ke J, Li MT, Huo YJ, et al. The Synergistic Effect of . Drug Des Devel Ther. 2021;15:3543-3560doi: 10.2147/DDDT.S318515.
Ke, J., Li, M. T., Huo, Y. J., Cheng, Y. Q., Guo, S. F., Wu, Y., Zhang, L., Ma, J., Liu, A. J., & Han, Y. (2021). The Synergistic Effect of . Drug design, development and therapy, 153543-3560. https://doi.org/10.2147/DDDT.S318515
Ke, Jia, et al. "The Synergistic Effect of ." Drug design, development and therapy vol. 15 (2021): 3543-3560. doi: https://doi.org/10.2147/DDDT.S318515
Ke J, Li MT, Huo YJ, Cheng YQ, Guo SF, Wu Y, Zhang L, Ma J, Liu AJ, Han Y. The Synergistic Effect of . Drug Des Devel Ther. 2021 Aug 14;15:3543-3560. doi: 10.2147/DDDT.S318515. eCollection 2021. PMID: 34429584; PMCID: PMC8375244.
Copy Download .nbib Format: NLM
Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074389
Ont Health Technol Assess Ser. 2010;10(12):1-38. Epub 2010 Jun 01.

UNLABELLED: In July 2009, the Medical Advisory Secretariat (MAS) began work on Non-Invasive Cardiac Imaging Technologies for the Diagnosis of Coronary Artery Disease (CAD), an evidence-based review of the literature surrounding different cardiac imaging modalities to ensure that appropriate...

Cite
Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(12):1-38
(2010). Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis. Ontario health technology assessment series, 10(12), 1-38.
"Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis." Ontario health technology assessment series vol. 10,12 (2010): 1-38.
Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(12):1-38. Epub 2010 Jun 01. PMID: 23074389; PMCID: PMC3377522.
Copy Download .nbib Format: NLM
The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy.

Tropical medicine & international health : TM & IH

Tong X, Li Z, Zhao J, Liu S, Fan H.
PMID: 34297877
Trop Med Int Health. 2021 Nov;26(11):1356-1366. doi: 10.1111/tmi.13659. Epub 2021 Aug 01.

OBJECTIVE: Tuberculous pleurisy (TP) is a common disease of extrapulmonary tuberculosis, but its diagnosis is challenging. Recently, studies have found that the pleural fluid interferon gamma release assay (PF-IGRA) has important diagnostic value in TP, but the sample size...

Cite
Tong X, Li Z, Zhao J, et al. The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Trop Med Int Health. 2021;26(11):1356-1366doi: 10.1111/tmi.13659.
Tong, X., Li, Z., Zhao, J., Liu, S., & Fan, H. (2021). The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Tropical medicine & international health : TM & IH, 26(11), 1356-1366. https://doi.org/10.1111/tmi.13659
Tong, Xiang, et al. "The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy." Tropical medicine & international health : TM & IH vol. 26,11 (2021): 1356-1366. doi: https://doi.org/10.1111/tmi.13659
Tong X, Li Z, Zhao J, Liu S, Fan H. The value of single or combined use of pleural fluid interferon gamma release assay in the diagnosis of tuberculous pleurisy. Trop Med Int Health. 2021 Nov;26(11):1356-1366. doi: 10.1111/tmi.13659. Epub 2021 Aug 01. PMID: 34297877.
Copy Download .nbib Format: NLM
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074402
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 01.

UNLABELLED: In February 2010, the Medical Advisory Secretariat (MAS) began work on evidence-based reviews of the literature surrounding three pharmacogenomic tests. This project came about when Cancer Care Ontario (CCO) asked MAS to provide evidence-based analyses on the effectiveness...

Cite
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2010;10(24):1-48
(2010). Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ontario health technology assessment series, 10(24), 1-48.
"Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis." Ontario health technology assessment series vol. 10,24 (2010): 1-48.
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 01. PMID: 23074402; PMCID: PMC3377519.
Copy Download .nbib Format: NLM
Showing 7885 to 7888 of 7888 entries